Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2018
Webcast and Conference Call today at 4:30 p.m. ET
Royalty revenue for the quarter increased to $67.2 million
Net income was $27.4 million, or $1.30 per diluted common share
Cash and marketable securities totaled $325.1 million
Phase 2a study initiated with EDP-938 against respiratory syncytial virus (RSV) infection in a human challenge study
Hepatitis B virus (HBV) candidate EDP-514 selected for clinical development in 2019
Enanta’s HBV program continues to move ahead as Enanta announces that it has selected EDP-514, a promising inhibitor of the HBV core protein, as its first development candidate in this program. A Phase 1 study of EDP-514, consisting of evaluation of single and multiple doses of drug in healthy volunteers and incorporating a Phase 1b arm in chronic HBV patients, is planned to begin in 2019.